Welcome to our dedicated page for CANNABIS BIOSCI INTL HLDG news (Ticker: CBIH), a resource for investors and traders seeking the latest updates and insights on CANNABIS BIOSCI INTL HLDG stock.
Cannabis Bioscience International Holdings (CBIH), based in Houston, Texas, is a pioneering company in the cannabis industry. Led by CEO Dante Picazo, CBIH focuses on cannabinoid research and innovation, aiming to establish industry standards. Recent achievements include appointing Mr. John E. Jones as Treasurer and Director, known for his strategic guidance and fiscal oversight in previous executive roles. CBIH's partnership with StoneBridge Advisory for company valuation and collaboration with Vita Biotech Research for funding clinical data collection trials highlight the company's commitment to cutting-edge research and strategic growth.
Rhea-AI Summary
Cannabis Bioscience International Holdings (CBIH) has appointed Mr. John E. Jones as its new Treasurer and Director. Mr. Jones brings a wealth of experience from his successful career in the business sector, with a focus on strategic acquisitions, mergers, and capital projects. His expertise is expected to bolster CBIH's position in the cannabis industry, particularly in cannabinoid research and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
-
Rhea-AI Summary
Cannabis Bioscience International Holdings, Inc. (CBIH) initiates a clinical trial for Orthocann, a new intra-articular cannabinoid-based injection for knee osteoarthritis. The company aims to assess its efficacy in treating knee cartilage damage and providing relief without the adverse effects of corticosteroid injections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Cannabis Bioscience International Holdings, Inc. (CBIH) announces the retirement of one billion shares by its CEO, Dante Picazo, contributing to a reduction in outstanding shares to approximately 9.4 billion. The market price of the shares is valued at $5 million, aiming to increase shareholder value. This move follows previous contributions by current management, totaling 5.5 billion shares since 2019, without a reverse stock split. The Company's commitment to innovation in medical formulations and biotechnology, supported by AI algorithms, reflects a focus on market integrity and scientific research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Cannabis Bioscience International Holdings (CBIH) appoints Brian Cuban as Advisory Board Member, bringing legal, corporate leadership, and mental health expertise. Cuban, brother of Mark Cuban, is a lawyer, author, and advocate with a history of recovery. His addition aims to enhance CBIH's mission of advancing cannabinoid medicine and improving patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
-
Rhea-AI Summary
Cannabis Bioscience International Holdings (CBIH) partners with Bull in Advantage for Investor Relations services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
-
Rhea-AI Summary
Cannabis Bioscience International Holdings, Inc. (CBIH) CEO Dante Picazo sends a letter to shareholders, highlighting the company's progress in developing formulations for various medical conditions, including osteoarthritis and depressive disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
Rhea-AI Summary
Cannabis Bioscience International Holdings (CBIH) achieved SEC effectiveness for its Form S-1 registration statement, aiming to start its own cannabis clinical trials using AI programs to optimize research processes and acquire clinical evidence for its intellectual property cannabinoid formulations. The company plans to treat cancer, PTSD, COVID-19, Herpes Zoster, chronic pain, and other conditions. CBIH is dedicated to representing Texas as a leader in the medicinal cannabis industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
-
Rhea-AI Summary
Cannabis Bioscience International Holdings, Inc. (CBIH) announces the declaration of its registration statement on Form S-1, filed under the Securities Act of 1933, as effective by the SEC. The company is offering 10,087,154,885 shares of its common stock at a price of $0.0008 per share, with 6,250,000,000 shares offered by the company and the remaining 3,837,154,885 shares by selling stockholders. The company has become a reporting company under Section 15(d) of the Securities Exchange Act of 1934, required to file annual, quarterly, and other reports with the SEC. The company offers services in clinical trials and cannabis-related education, intending to conduct clinical trials of its own cannabidiol products and sell them.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.33%
Tags
-
Rhea-AI Summary
Cannabis Bioscience International Holdings launches new website as part of rebranding strategy, emphasizing research and production of cannabis as medicine. The website provides information on future plans and invites qualified investors to review projects. Contact ir@cbih.net for more information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Cannabis Bioscience International Holdings (formerly China Infrastructure Construction Corp.) has received approval for its name and ticker symbol change from FINRA. The new ticker symbol is CBIH. No action required by current shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of CANNABIS BIOSCI INTL HLDG (CBIH)?
The current stock price of CANNABIS BIOSCI INTL HLDG (CBIH) is $0.0006 as of December 20, 2024.
What is the market cap of CANNABIS BIOSCI INTL HLDG (CBIH)?
The market cap of CANNABIS BIOSCI INTL HLDG (CBIH) is approximately 6.3M.
Who is the CEO of Cannabis Bioscience International Holdings (CBIH)?
Dante Picazo is the CEO of CBIH, leading the company's efforts in cannabinoid research and innovation.
What recent achievement did CBIH announce?
CBIH recently appointed Mr. John E. Jones as Treasurer and Director, known for his strategic guidance and fiscal oversight.
What partnerships has CBIH formed recently?
CBIH has partnered with StoneBridge Advisory for company valuation and Vita Biotech Research for funding clinical data collection trials.
Where is Cannabis Bioscience International Holdings (CBIH) based?
CBIH is based in Houston, Texas, at the forefront of the cannabis industry.
What is the focus of CBIH?
CBIH focuses on cannabinoid research and innovation, aiming to establish industry standards.
How does CBIH describe its recent collaborations?
CBIH's recent collaborations with StoneBridge Advisory and Vita Biotech Research highlight the company's commitment to cutting-edge research and strategic growth.
Who is Mr. John E. Jones, recently appointed by CBIH?
Mr. John E. Jones is a former 101st Airborne Division sergeant with a 35-year career in the business sector, known for his transformative role in the QSR industry.
What is CBIH's strategic focus for the future?
CBIH aims to advance its research in cannabinoid innovations and set industry standards under the leadership of CEO Dante Picazo.
Why is CBIH collaborating with Vita Biotech Research?
CBIH's collaboration with Vita Biotech Research aims to fund clinical data collection trials, accelerating the company's progress towards scientific and commercial goals.
How does CBIH approach risk management in its business strategy?
CBIH adopts a risk management strategy by isolating each medical formulation into a unique legal entity, aiming to simplify financing, partnerships, and intellectual property processes.
What are the potential benefits of CBIH's collaboration with Vita Biotech Research?
The collaboration is expected to bolster the credibility of CBIH's research among leading pharmaceutical companies and pave the way as pioneers in medical cannabis clinical research.
CANNABIS BIOSCI INTL HLDG
OTC:CBIH
CBIH Rankings
CBIH Stock Data
6.33M
4.79B
54.67%
Drug Manufacturers - Specialty & Generic
Healthcare
United States of America
Houston